Jingran Ji, Jaideep Sandhu, Chongkai Wang, Marwan Fakih
{"title":"Metastatic pattern is a prognostic factor in BRAFV600E mutant colorectal cancer","authors":"Jingran Ji, Jaideep Sandhu, Chongkai Wang, Marwan Fakih","doi":"10.1016/j.ctarc.2023.100714","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p>Despite recent advancements in the treatment of metastatic <em>BRAF<sup>V600E</sup></em> colorectal cancer (CRC), prognosis remains poor. However, a some patients with <em>BRAF<sup>V600E</sup></em> disease have superior outcomes compared to the overall cohort and the prognostic factors associated with this improved survival are not well understood.</p></div><div><h3>Methods</h3><p>We conducted a single center retrospective review of patients with metastatic CRC and available next generation sequencing data. Patients with confirmed <em>BRAF<sup>V600E</sup></em> disease were selected for the final analysis. We collected baseline demographic characteristics, concurrent mutations, and metastatic pattern. The primary endpoint was overall survival (OS). Univariate and multivariable logistic regression was used to examine the association between baseline concurrent somatic mutations and sites of metastatic disease with survival.</p></div><div><h3>Results</h3><p>Of 466 patients with metastatic CRC, 50 harbored <em>BRAF<sup>V600E</sup></em> disease and 42 were included in the final analysis. The median OS in this cohort was 18.7 months (95% CI: 5.55–31.8). There was no association between baseline concurrent somatic mutations and OS. On univariate analysis, patients with lymph node only disease at the time of metastatic disease were more likely to have longer OS (hazard ratio [HR] = 0.30, 95% CI: 0.09–0.98, <em>p</em> = 0.047) and patients with peritoneal disease were more likely to have shorter OS (HR = 2.78, 95% CI: 1.12–6.88, <em>p</em> = 0.03). However, these associations did not retain statistical significance on multivariable analysis.</p></div><div><h3>Conclusions</h3><p>The pattern of metastatic disease in <em>BRAF<sup>V600E</sup></em> CRC may be a prognostic factor and future studies are needed to better understand the underlying mechanisms and potentially change clinical practice for a select patient population.</p></div><div><h3>MicroAbstract</h3><p>Select patients with metastatic <em>BRAF<sup>V600E</sup></em> colorectal cancer may have better than expected survival but are not well characterized. We conducted a retrospective review of 42 patients with metastatic <em>BRAF<sup>V600E</sup></em> colorectal cancer and showed that lymph node only disease at the time of metastatic disease was associated with superior survival.</p></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"35 ","pages":"Article 100714"},"PeriodicalIF":0.0000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer treatment and research communications","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2468294223000357","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0
Abstract
Background
Despite recent advancements in the treatment of metastatic BRAFV600E colorectal cancer (CRC), prognosis remains poor. However, a some patients with BRAFV600E disease have superior outcomes compared to the overall cohort and the prognostic factors associated with this improved survival are not well understood.
Methods
We conducted a single center retrospective review of patients with metastatic CRC and available next generation sequencing data. Patients with confirmed BRAFV600E disease were selected for the final analysis. We collected baseline demographic characteristics, concurrent mutations, and metastatic pattern. The primary endpoint was overall survival (OS). Univariate and multivariable logistic regression was used to examine the association between baseline concurrent somatic mutations and sites of metastatic disease with survival.
Results
Of 466 patients with metastatic CRC, 50 harbored BRAFV600E disease and 42 were included in the final analysis. The median OS in this cohort was 18.7 months (95% CI: 5.55–31.8). There was no association between baseline concurrent somatic mutations and OS. On univariate analysis, patients with lymph node only disease at the time of metastatic disease were more likely to have longer OS (hazard ratio [HR] = 0.30, 95% CI: 0.09–0.98, p = 0.047) and patients with peritoneal disease were more likely to have shorter OS (HR = 2.78, 95% CI: 1.12–6.88, p = 0.03). However, these associations did not retain statistical significance on multivariable analysis.
Conclusions
The pattern of metastatic disease in BRAFV600E CRC may be a prognostic factor and future studies are needed to better understand the underlying mechanisms and potentially change clinical practice for a select patient population.
MicroAbstract
Select patients with metastatic BRAFV600E colorectal cancer may have better than expected survival but are not well characterized. We conducted a retrospective review of 42 patients with metastatic BRAFV600E colorectal cancer and showed that lymph node only disease at the time of metastatic disease was associated with superior survival.
期刊介绍:
Cancer Treatment and Research Communications is an international peer-reviewed publication dedicated to providing comprehensive basic, translational, and clinical oncology research. The journal is devoted to articles on detection, diagnosis, prevention, policy, and treatment of cancer and provides a global forum for the nurturing and development of future generations of oncology scientists. Cancer Treatment and Research Communications publishes comprehensive reviews and original studies describing various aspects of basic through clinical research of all tumor types. The journal also accepts clinical studies in oncology, with an emphasis on prospective early phase clinical trials. Specific areas of interest include basic, translational, and clinical research and mechanistic approaches; cancer biology; molecular carcinogenesis; genetics and genomics; stem cell and developmental biology; immunology; molecular and cellular oncology; systems biology; drug sensitivity and resistance; gene and antisense therapy; pathology, markers, and prognostic indicators; chemoprevention strategies; multimodality therapy; cancer policy; and integration of various approaches. Our mission is to be the premier source of relevant information through promoting excellence in research and facilitating the timely translation of that science to health care and clinical practice.